Fibrosis is associated with diverse factors, some of them treatable or preventable, which need to be addressed considering the high prevalence and course of fibrosis in these patients.
Liver biopsy is being progressively eliminated from clinical practice as a tool to evaluate the progression to liver fibrosis and to undergo therapeutic decisions in HIV-HCV-coinfected patients. Transient elastometry (TE) and, to a lesser degree, different liver fibrosis indexes (LFI) are the preferred non-invasive methods for assessing liver fibrosis. These techniques seem to be very reliable for identifying extreme stages of fibrosis, but less accurate for intermediate stages [1] [2] [3] . These non-invasive methods have been validated in patients with liver disorders of different aetiology and severity, especially chronic HCV infection, who simultaneously underwent liver biopsy [4] [5] [6] [7] . In approximately 50-70% of patients, liver fibrosis can be accurately assessed by LFI and in 90% by TE. Discordant results can be attributed to TE or to liver biopsy indistinctly, a technique with a 10-30% error rate [1, 8] . In many cases, TE can be used instead of liver biopsy and this is one of the reasons for its introduction in daily clinical practice.
Studies based on HIV-HCV-coinfected patients are more infrequent, partly because of the sociological particularities of intravenous drug users (IDU), who are less likely to undergo liver biopsies or to obtain
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Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV Introduction adequate adherence to medical care [6, 7, [9] [10] [11] [12] . However, the accelerated fibrosis progression in these individuals makes them especially vulnerable to developing liver cirrhosis [13, 14] . Thus, it is important to know the factors leading to this poor evolution, especially those that can be prevented.
The main goals of this large cross-sectional study, conducted in a large cohort of HIV-HCV-coinfected patients, are to compare the value of TE versus LFI and liver biopsies to identify patients with progressive stages of liver fibrosis according to pre-established cutoff levels, and to identify the different sociodemographic, HCV, HIV and antiretroviral therapy (ART) variables associated with progression to significant fibrosis, advanced fibrosis and cirrhosis.
Methods

Study patients and data collection
A total of 1,074 HIV-HCV-coinfected patients, mostly IDU, who were identified during the period from October 2007 to November 2009 in two large university hospitals of Asturias (Northwestern Spain) were studied. Patients older than 18 years with active HCV coinfection, demonstrated by serology and plasma detection of viral RNA, were enrolled in the study. Clinical and analytical data were obtained at enrolment, in addition to undergoing TE to determine the degree of liver fibrosis. Historical data, such as dates of first positive serologies, nadir CD4 + T-cell count, CDC stage and previous ART and its effectiveness were obtained from medical charts.
Pregnant women and those individuals in whom there were technical difficulties for obtaining reliable TE readings were excluded from the study (n=43). In addition, patients with an acute episode of cytolysis or cholestasis were excluded because the TE reading could be altered by these factors [15] , as well as patients under current anti-HCV therapy and those without active HCV infection (defined as undetectable HCV RNA). However, 99 patients who were non-responders or relapsers to previous anti-HCV therapy were also included.
Demographic and clinical data, focusing on present and past drug use and ethanol consumption, were collected. Ethanol consumption >50 g daily for ≥5 years was considered as alcohol abuse. The date of HCV infection was also recorded, although most patients were not aware of the precise date. In such cases, it was considered that patients were infected 1 year after starting intravenous drugs, as reported previously [16, 17] , considering the widespread HCV infection in this group in Spain and the extended practice of sharing needles.
Main data regarding HIV infection were also collected and included date of the first positive HIV serology, CDC clinical category, current HIV plasma viral load, and nadir and current CD4 + T-cell counts. The difference between current and nadir CD4 + T-cell counts was called CD4 + T-cell gain and the final immune status of the patient was classified as either <350 or ≥350 CD4 + T-cells/mm 3 . Past and present ART was also registered, calculating the following variables: total time of ART, total time on protease inhibitors (PIs; alone or ritonavir-boosted), total time on non-nucleoside reverse transcriptase inhibitors (NNRTIs), total time on other regimens based on nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs; mono-, bi-or triple therapy) and the total time of voluntary ART discontinuation.
Quality of ART was evaluated considering the persistence of virological supression. Thus, times on optimal (plasma HIV RNA≤400 copies/ml) and suboptimal (plasma HIV RNA>400 copies/ml) therapy were calculated. In the absence of HIV viral load measurements, time on mono-and bitherapies were considered as suboptimal periods of therapy. Percentage of time on ART for both HIV and HCV infections, and the treatment efficacy or percentage of time with undetectable plasma HIV viral load, was also calculated.
All patients underwent standard care, including routine non-invasive procedures; therefore, no formal written approval was necessary according to our institution's and country's regulations, as verbal informed consent was sufficient and was obtained from all patients.
Laboratory methods
Enzyme immunoassay (MEIA AxSYM; Abbott Diagnostics, Abbott Park, IL, USA) was used for screening of HIV and HCV antibodies and for the presence of hepatitis B surface antigen (HBsAg). Patients who tested positive for HBsAg were also analysed for hepatitis delta virus (HDV) antibodies (EIA-HDV; DiaSorin, Saluggia, Italy). HIV RNA and HCV RNA were measured by quantitative PCR (Cobas TaqMan; Roche Diagnostics, Branchburg, NJ, USA) and HCV genotypes were measured by line probe assay (Versant HCV; Siemens Healthcare Diagnostics, Deerfield, IL, USA). CD4 + T-cell counts, platelets, total cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (GGT) were assessed by routine laboratory methods at entry in the study to calculate LFI: AST and platelets were used to calculate the APRI index [18] , age, platelets, total cholesterol and GGT were used for Forns index [19] , and age, AST, ALT and platelets were used for FIB-4 [20] . LFI cutoffs for significant liver fibrosis were those previously established: APRI≥1.50, Forns≥6.90 and FIB-4≥3. 25 .
Histological evaluation of liver fibrosis was done according to the Metavir quantitative scoring system from F0 to F4 [21] . An experienced liver pathologist reviewed and reclassified liver biopsies that were codified in other scales than the Metavir system. Liver fibrosis was assessed by TE using FibroScan (EchoSens, Paris, France) following pre-established methods [22] . Liver stiffness was the median value of ≥10 measurements obtained from the right liver lobe through one or two right thoracic intercostal spaces, expressed in kPa. The success rate was calculated as the number of validated measurements divided by the total number of assessments. The median value of successful measurements was considered representative of liver stiffness only if the interquartile range (IQR) of all validated measurements was <30% of the median value with a success rate >60%.
Patients were divided into four groups according to FibroScan measurements: FS1, FS2, FS3 and FS4. These groups reflect the progressive stage of liver fibrosis in analogy with the F0-1, F2, F3 and F4 histological stages of the Metavir scoring system. Thus, a cutoff of 7.2 kPa was considered to indicate the start of significant fibrosis or FS2, 9.4 kPa as the start of advanced fibrosis and 14.0 kPa as indicative of liver cirrhosis, in accordance with previous reports that compared TE with liver biopsy [1] [2] [3] [4] [5] [6] as well as the cutoff values used in clinical practice in different European hospitals [7, [10] [11] [12] , although a complete agreement among the authors is lacking.
Statistical analyses
Continuous variables were expressed as medians and IQRs because of their non-normal distributions and categorical variables were expressed as numbers and percentages of the total available data. Continuous variables were compared by using the Spearman's correlation coefficient. Comparisons among different liver stiffness groups were done with the Kruskal-Wallis test and χ 2 test, as appropriate. Stepwise logistic regressions were carried out for multivariate analysis considering the different degrees of fibrosis as dependent variables. Variables that showed a significant relationship with the grade of fibrosis at a value of P<0.05 were introduced as predictor factors. LFI values were excluded from this analysis because of their well-known predictive value on fibrosis.
Receiver operating characteristic (ROC) curves and the area under the ROC (AUROCs) curves were used to compare the diagnostic accuracy among liver biopsies measured by Metavir, TE measurements and LFI using previously defined cutoffs. Statistical analysis was done with the SPSS version 15.0 statistical package (SPSS, Inc., Chicago, IL, USA). All the values were two-tailed and a P-value <0.05 was considered as statistically significant.
Results
Description of the cohort
The study group was composed of 805 patients, 72.2% of whom were male, and 95.2% of whom Figure 1 ). HCV genotypes 1, 2, 3 and 4 were found in 62.4%, 1.7%, 23.4% and 12.5%, respectively. Median (IQR) plasma HCV RNA was 6.13 log 10 UI/ml (5.71-6.58). Chronic HBV coinfection was observed in 27 (3.4%) patients and HDV in 7 (0.9%) of those who were HBsAg-positive.
Median (IQR) nadir CD4 + T-cell values were 202 cells/mm 3 (84-312); undetectable plasma HIV RNA was observed in 69.7% patients and the remainder had a median (IQR) HIV RNA of 3.59 log 10 copies/ml (2.28-4.61). In 126 (15.7%) patients a previous liver biopsy was available, which had been performed a median (IQR) of 4.03 years (1.59-5.89) before. Specific aspects related to the comparison of the biopsy and TE are described below.
Univariate analyses
Patients were stratified into four groups according to their TE measurements (Table 1) . A significant association with progressive liver fibrosis was found for the following sociodemographic variables: older age, male sex, previous history of alcohol abuse, current intravenous drug use and cannabis use. Regarding HIV infection, fibrosis progression was significantly associated with a longer time of HIV infection and poorer immune markers, such as lower nadir current CD4 + T-cell count, poorer CD4 + T-cell gain under ART and presence of AIDS-defining clinical events. Higher liver fibrosis was also associated with a significantly longer time of HCV infection, HCV genotype 3 and prior failure to HCV chemotherapy. In addition, all laboratory data considered (ALT, AST, GGT, total cholesterol and platelets) and the LFI constructed from them (APRI, Forns and FIB-4), as well as liver biopsy results, were significantly associated with fibrosis as evaluated by TE.
Antiretroviral therapy
Details and evaluation of ART are summarized in Table 2 . Patients with more advanced stages of liver fibrosis showed a significantly longer duration of HCV and HIV infections. Therefore, at the time of the study they had received ART for longer and the rate of ART-naive patients was lower in this group. Considering the three main types of ART, there was a significant association between more advanced fibrosis and longer exposure to PIs, whereas there were no differences regarding NNRTIs or NRTIs. There were no differences in ART discontinuation among the groups. In addition, at the time of TE assessment, a significantly higher PI use rate was found in patients with advanced fibrosis, whereas NNRTIs were more frequently used in FS1 individuals. Patients with advanced fibrosis received suboptimal ART for a longer period of time. The HIV and HCV follow-up under ART was associated with higher degrees of fibrosis, but not the time rate under optimal ART.
Multivariate analyses
Results of the multivariate analyses for the different stages of liver fibrosis assessed by TE are summarized in Table 3 . When LFI were included in the analysis, Forns (P<0.001) and FIB-4 (P=0.02) indexes, but not APRI (P=0.5), displaced all the laboratory variables in the three cutoff points for fibrosis (JAC et al., data not shown). Six variables were always associated with liver fibrosis independently of the TE cutoff values considered: duration of HCV infection, ethanol consumption, unsuccessful past HCV therapy, CDC category C3, thrombocytopaenia and increased AST values.
Correlation between TE, LFI and biopsy
There was a significant correlation between TE and LFI (Forns r=0.60, FIB-4 r=0.58 and APRI r=0.52; P<0.001 for each). The accuracy of these LFI at their traditional cutoff values to detect significant advanced fibrosis and cirrhosis by TE, are shown in Table 4 . In general, their sensitivity increased in parallel to liver fibrosis. The AUROC values obtained by the APRI, FIB-4 and Forns indexes versus TE increased significantly with the fibrosis stage, being more useful for the diagnosis of advanced fibrosis and cirrhosis (Table 4) .
In 107 (84.9%) of the 126 patients with a previous liver biopsy, TE revealed the same (n=71) or higher (n=36) stages of fibrosis, whereas in the remaining 19 (15.1%) patients TE resulted in lower degrees of fibrosis in comparison with biopsy. The AUROC (95% CI) value obtained by TE to predict significant histological fibrosis (Metavir ≥F2) was 0.83 (0.76-0.90), for advanced fibrosis (Metavir ≥F3) was 0.89 (0.83-0.95) and for cirrhosis (Metavir =F4) was 0.87 (0.80-0.95).
Discussion
Half of the HIV-infected population in Spain are also coinfected with HCV because of the predominance of intravenous drug use as the transmission route [17] . Prevalence of HCV infection was almost 100% in these patients, who become infected during the first year of needle sharing [16, 17] . The rates of significant and advanced liver fibrosis and cirrhosis were high in our study, but were in agreement with the 25-50% rate usually accepted after 25 years of HIV-HCV coinfection [7, [9] [10] [11] 13, 23, 24] .
The usefulness of TE versus liver biopsy has been validated by ROC curves in previous reports [4] [5] [6] [7] 9, 10, 12] . The best discriminative points for the diagnosis of liver fibrosis, classified as mild, significant, severe and cirrhosis (equivalent to Metavir F0-1, F2, F3 and F4, respectively) have been calculated, although a complete agreement on TE cutoffs is still lacking. Our patients were stratified into different fibrosis stages according to predefined TE ranges because of the small number of liver biopsies, which had been obtained several years before the TE assessment. This factor could explain the lower AUROC observed in our study when compared with previous reports (AUROC=0.83 for ≥FS2, 0.89 for ≥FS3 and 0.87 for FS4). Only if HBsAg-positive. FibroScan scores for each group were as follows: <7.2 kPa for the FS1 group, 7.2-9.3 kPa for the FS2 group; 9.4-13.9 kPa for the FS3 group and >14.0 kPa for the FS4 group. ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; HDV, hepatitis delta virus; NS, non-significant.
The individuals best characterized by TE were in the two extremes of the fibrosis range: liver cirrhosis and mild or absent fibrosis. By contrast, TE showed poor discriminative ability between groups FS2 and FS3, which mostly overlapped. Therefore, a simplification of the fibrosis classification could be reasonable, reducing the spectrum of fibrosis to three groups and establishing the cutoff for significant fibrosis to 7.2-7.4 kPa, and for cirrhosis to 12.6 kPa, as previously reported [1, 3] .
The results of our study on a large population confirm typical fibrosis risk factors such as age, male sex, alcohol abuse, duration of HCV infection and failure to achieve viral eradication after HCV treatment [24] [25] [26] [27] . The effect of alcohol was especially devastating in our series, and our findings emphasize the value of alcohol abstinence in HIV-HCV-coinfected individuals as the main effective preventive measure against fibrosis. In addition, alcohol, drug abuse and the associated psychosocial conditions drive these patients away from anti-HCV therapy.
Longitudinal assessments of liver fibrosis by biopsy and TE demonstrated non-progression, or even reduction, of fibrosis in patients who suppressed HCV compared with those without viral response [28] [29] [30] [31] [32] . Similarly, failure of HCV therapy was an important risk factor for more advanced fibrosis in our cross-sectional study. Our study also supports prior reports regarding the association of HCV genotype 3 with higher fibrosis Includes time during discontinuation of antiretroviral therapy (ART). FibroScan scores for each group were as follows: <7.2 kPa for the FS1 group, 7.2-9.3 kPa for the FS2 group; 9.4-13.9 kPa for the FS3 group and >14.0 kPa for the FS4 group. NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NS, non-significant; PI, protease inhibitor. progression rates and mortality [24, 33, 34] ; therefore, anti-HCV therapy should be promoted in carriers of this genotype because of its better response to treatment and to its spread among IDU in Europe [17, 34] . In general, a good parallel between HIV infection course and liver fibrosis development was observed in ours and other studies [23, 26] . CD4 + T-cell counts were significantly lower in the groups with advanced fibrosis, and AIDS-defining clinical events were also associated with fibrosis in the multivariate analysis. ART could also improve the course of liver disease by preventing HCV and HIV replications, increasing CD4 + T-cells, slowing liver fibrogenesis and even decreasing the decompensation and death rates of cirrhotic patients [25, 26, 35, 36] .
The greater use of PIs in patients with more advanced fibrosis was constantly observed throughout the study. This finding could be a result of the lower hepatotoxicity, low rate of interactions with methadone and higher genetic barrier of PIs compared with NNRTI. Some reports have found associations between liver fibrogenesis and higher exposure to either PIs or NNRTIs [25, 37, 38] . A recent study based on consecutive liver biopsies found that the response to anti-HCV therapy and the presence of an effective ART were related to slower liver fibrosis [32] . The value of an optimal ART regimen with sustained HIV suppression must be emphasized, regardless of the drugs used, as virological failure is a predictive factor of liver fibrosis in HIV-HCV-coinfected patients.
We also compared TE with some simultaneously obtained LFI markers, broadly evaluated in mono-and coinfected patients [3, 4, 12, 18, 20, 39] . The diagnostic performance of these LFI compared with TE was relatively low at low stages of fibrosis, improving with its progression. Among the three LFI markers, Forns index was the most sensitive. TE is a direct method, easily reproduced and, as opposed to LFI markers, it is not influenced by other factors relatively common in HIV-HCV-coinfected individuals, such as thrombocytopaenia and ART-induced liver function test abnormalities [1] [2] [3] [4] 40] ; therefore, LFI markers could be used in clinical practice as complementary tests to TE.
Limitations of our cross-sectional study include the scarce and outdated liver biopsies; however, this shortcoming would only affect the comparisons between TE and Metavir scores, as the rest of parameters evaluated were obtained simultaneously with the TE assessment. By contrast, strengths of the study include the large number of individuals enrolled from two large and nearby hospitals, with large homogeneity in patients care and follow-up procedures, as well as the many covariates evaluated.
In conclusion, this study shows the value of TE in clinical practice for staging and follow-up of liver fibrosis in HIV-HCV-coinfected patients. After 25 years of HCV infection, the prevalence of significant or higher fibrosis reached half of the population studied, emphasizing the value of starting anti-HCV therapy in the appropriate candidates as soon as possible. Some of the factors considered in the study, such as the deleterious effect of genotype 3, alcohol consumption and unsuccessful HCV therapy, or the beneficial role of optimal highly active antiretroviral therapy, have clear practical implications to slow down the progression to liver fibrosis.
